Dyne Therapeutics, Inc. has announced that its investigational therapeutic, DYNE-251, for Duchenne muscular dystrophy (DMD), has been granted FDA orphan drug and rare pediatric disease designations.

The Air Force and Navy are working on an agreement that will allow each of their software factories to share more code and products. The agreement is close to being finalized Navy CTO Jane Rathbun ...

Dyne Therapeutics Inc. is advancing novel therapeutics for people living with genetically driven neuromuscular diseases. Representatives from the company recently presented a poster showcasing ...

Dyne Therapeutics Inc. presented their most recent work to advance novel therapeutics for facioscapulohumeral muscular dystrophy (FHSD). FSHD is an autosomal dominant genetic disorder characterized by ...

FAIRFAX, Va.--(BUSINESS WIRE)--ECS, a leader in advanced technology, science, and engineering solutions, has been selected as an authorized reseller of U.S. Air Force (USAF) Platform One (P1) products ...